637 upcoming projects, followed from site selection through to validation and first batch. Capacity, dosage form, capex, EPCs, equipment orders, and verified manufacturer contacts.
As of 16 October 2026, Blackridge Research & Consulting tracks 637 upcoming pharmaceutical plant projects worldwide, representing $185 billion in announced capital expenditure.
Scroll to zoom, drag to pan, click a country to zoom into it. One dataset shades the map at a time, switch below.
Halo area is proportional to the active dataset in that region. Hover any country for the region totals that cover it.
zoom 1.0x
in the full database, filtered to your territory.
What it is
A market intelligence platform tracking pharmaceutical manufacturing projects worldwide, from the first capacity commitment and incentive application through permitting, process design, construction, equipment install, qualification, validation, and commercial release. Every record carries verified investment values, production capacity, modality, timelines, stakeholders, tenders, and decision-maker contacts.
Engineering firms, cleanroom and process equipment suppliers, and contract manufacturers use it to find new facilities while design is still open, and follow each one through construction, validation and regulatory approval.
Coverage begins with investment incentive filings, site acquisitions, environmental permits and manufacturer capacity announcements, read in the local language before a facility is confirmed.
Manufacturer or CDMO, engineering and construction firm, cleanroom and HVAC contractors, and process and packaging equipment suppliers are mapped to each facility with verified contacts.
Each facility carries its stage, from site selection and design through construction and qualification to validation and first commercial batch, with an alert when a watched facility moves.
Capacity, dosage form and contract awards are reconciled against two independent sources, cited, and dated with the last verification, before they reach a record.
Pipeline Preview
Ranked by announced capex, these are the ten largest pharmaceutical manufacturing projects in the pipeline; each full record carries dosage form and capacity, engineering and equipment awards, and named manufacturer contacts.
| # | Project | Location | Capacity | Capex | Stage | Companies | Updated |
|---|---|---|---|---|---|---|---|
| 1 | BC - New Albany Pharmaceutical Manufacturing Plant | Ohio, United States | Not disclosed | $22B | Announced | 1 | 2026-10-02 |
| 2 | LLY - Lebanon Medicine Foundry | Indianapolis, United States | Not disclosed | $18B | On-going / Under Construction | 51 | 2026-06-11 |
| 3 | LLY - Project Savannah Biomanufacturing Facility | Texas, United States | Not disclosed | $6.5B | Planning | 4 | 2026-07-24 |
| 4 | LLY - Huntsville Medicines Manufacturing Plant | Alabama, United States | Not disclosed | $6B | Planning | 1 | 2026-07-02 |
| 5 | NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant | North Carolina, United States | Not disclosed | $4.1B | On-going / Under Construction | 11 | 2026-02-19 |
| 6 | LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion | Wisconsin, United States | Not disclosed | $4B | Planning | 5 | 2026-08-16 |
| 7 | EDCL - Gopalganj Vaccine Manufacturing Plant | Dhaka Division, Bangladesh | Not disclosed | $4B | Planning | 1 | 2023-11-22 |
| 8 | LLY - Fogelsville Injectable Medicine and Device Manufacturing Facility | Pennsylvania, United States | Not disclosed | $3.5B | Planning | 1 | 2026-05-21 |
| 9 | FF - Holly Springs Cell Culture Biomanufacturing Plant | North Carolina, United States | Not disclosed | $3.2B | On-going / Under Construction | 3 | 2026-03-18 |
| 10 | LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant | Netherlands | Not disclosed | $3B | Planning | 1 | 2026-04-03 |
Who is building
The most active owners and developers in the pipeline, ranked by the number of projects they hold, with the stage those projects have reached. Select a company to get its full project list and verified contacts.
Blackridge Research & Consulting tracks 533 owners and developers across the pharmaceutical plant pipeline. The most active is Novartis (USA), Inc, with 9 projects.
Top 25 of 533 companies
Market intelligence
Blackridge tracks 533 owners and developers across the pharmaceutical plant pipeline. The 25 most active hold 96 projects between them, led by Novartis (USA), Inc (9), Eli Lilly and Company, Inc. (8) and Hikma Pharmaceuticals (USA) Inc. (6).
The five busiest account for 33% of the projects held by the top 25, so the pipeline is spread across a broad field of builders rather than a few dominant ones.
All of the top 25 are owners.
Across their projects, 34% are already past contract award. Novartis (USA), Inc has the most in that phase, with 4 projects at award or under construction.
Full profiles for all 533 companies, with their project lists, contract awards and verified contacts, are in the database.
Company questions
Ranked by the number of upcoming projects they hold as owner or developer, the most active pharmaceutical plant companies are Novartis (USA), Inc (9), Eli Lilly and Company, Inc. (8), Hikma Pharmaceuticals (USA) Inc. (6), AstraZeneca Plc (5) and Genentech, Inc. (4). Blackridge tracks 533 companies across the pipeline in total.
Blackridge Research & Consulting tracks 533 owners and developers with upcoming pharmaceutical plant projects. The 25 most active hold 96 projects between them.
By number of projects, Novartis (USA), Inc is the most active, with 9 upcoming projects as owner. Of these, 4 are past contract award and 5 in study, planning or design. Eli Lilly and Company, Inc. follows with 8 projects.
Counting projects at contract award, pre-construction or under construction, the leaders are Novartis (USA), Inc (4), Gennecs LLC (3) and FUJIFILM Diosynth Biotechnologies (3).
Of the projects held by the 25 most active companies, 34% are already past contract award, and the rest are in study, planning, design or announced.
Novartis (USA), Inc holds 9 upcoming pharmaceutical plant projects as owner. Of these, 4 are past contract award and 5 in study, planning or design. It ranks #1 of the 533 companies Blackridge tracks by project count.
Eli Lilly and Company, Inc. holds 8 upcoming pharmaceutical plant projects as owner. Of these, 2 are past contract award, 5 in study, planning or design and 1 announced. It ranks #2 of the 533 companies Blackridge tracks by project count.
Hikma Pharmaceuticals (USA) Inc. holds 6 upcoming pharmaceutical plant projects as owner. Of these, 1 is past contract award, 4 in study, planning or design and 1 announced. It ranks #3 of the 533 companies Blackridge tracks by project count.
AstraZeneca Plc holds 5 upcoming pharmaceutical plant projects as owner. Of these, 2 are past contract award, 2 in study, planning or design and 1 announced. It ranks #4 of the 533 companies Blackridge tracks by project count.
Genentech, Inc. holds 4 upcoming pharmaceutical plant projects as owner. Of these, 1 is past contract award, 1 in study, planning or design and 2 announced. It ranks #5 of the 533 companies Blackridge tracks by project count.
Recent intelligence
The latest pharmaceutical plant project news from around the world: announcements, permits, contract awards, groundbreakings and expansions, published as they are reported.
Market Intelligence
Nine stages in four phase families, each cell sized by the number of tracked projects at that stage, running from the earliest signals through to validation and first batch.
| Stage | Projects | Capacity | CapEx |
|---|
Where the tracked pipeline actually sits. Counts come straight from the live database and are compared against the busiest region, not against a total: the regions overlap, so they are never added together.
Bars are scaled to the busiest region. A project in a country belonging to more than one grouping is counted in each, so these figures are not additive.
Market intelligence
Of the 637 upcoming pharmaceutical plant projects tracked, 35% are at contract award, pre-construction or under construction, 52% are in study, planning or design and 13% have only been announced. Planning is the largest single stage, with 278 projects.
The 222 projects past contract award carry $83 billion in capital expenditure, the part of the pipeline where equipment and construction packages are being let now.
Projects past award average $374 million each, against $206 million for those still in study, planning or design.
Europe holds the most tracked projects, 212 or 33% of the pipeline, followed by Asia-Pacific (170) and North America (170).
By announced investment, North America leads with $121 billion and also has the largest average ticket, $710 million per project.
Construction is furthest along in Africa, where 43% of tracked projects are past contract award, compared with 17% in Latin America.
Every project behind these figures, with its stage history, contractors and verified contacts, is in the full database.
FAQ
About the database
Coverage and data
Market fundamentals
Data quality and methodology
Plans and getting started
Get Started
Join equipment makers, engineering firms, EPCs, and investors who use the database to stay ahead of the worldwide manufacturing build-out.
,%20Inc_82253.png){kind=small}
%20Inc._86398.png){kind=small}
_10005.png){kind=small}
_22869.png){kind=small}